Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma

Mostrar otras versiones (1)

BACKGROUND/AIMS: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hee Jeong, Jo, Jae-Cheol, Lee, Yoo Jin, Lee, Myung Won, Kim, Do Young, Shin, Ho Jin, Im, Sung Nam, Lee, Ji Hyun, Bae, Sung Hwa, Do, Young Rok, Lee, Won Sik, Kim, Min Kyung, Jung, Jina, Lee, Jung Min, Kim, Ju-Hyung, Baek, Dong Won, Sohn, Sang-Kyun, Moon, Joon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993097/
https://www.ncbi.nlm.nih.gov/pubmed/36698051
http://dx.doi.org/10.3904/kjim.2022.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993097/
https://www.ncbi.nlm.nih.gov/pubmed/36698051
http://dx.doi.org/10.3904/kjim.2022.183

Ejemplares similares